Ragde H, Blasko J C, Grimm P D, Kenny G M, Sylvester J, Hoak D C, Cavanagh W, Landin K
Northwest Hospital, Seattle, Washington, USA.
Semin Surg Oncol. 1997 Nov-Dec;13(6):438-43. doi: 10.1002/(sici)1098-2388(199711/12)13:6<438::aid-ssu8>3.0.co;2-b.
In recent years, there has been a resurgence of interest in interstitial radiation as a cost-effective and efficient method of treating organ-confined prostate cancer. We describe our 7- and 8-year results with transperineal Iodine-125 and Palladium-103 implantation. A total of 551 consecutive patients were treated. Of these, 320/551 (58%) received implant alone (Group I), and 231/551 (42%)--considered higher risk patients--were also treated with a modest dose (45 Gy) of external beam irradiation (Group II). The median follow-up for Group I was 55 months, and for Group II, 60 months. At 7 years, the actuarial freedom from biochemical failure (prostate-specific antigen (PSA) < or = 1.0 ng/mL) was 80% in Group I patients, and, at 8 years, 65% in Group II patients. Morbidity was minimal if patients had not undergone prior transurethral prostate resections. The results indicate that interstitial radiation is a valid treatment for clinically localized prostate cancer.
近年来，作为一种治疗器官局限性前列腺癌的经济有效方法，组织间放射治疗重新引起了人们的关注。我们描述了经会阴碘-125和钯-103植入治疗7年和8年的结果。共有551例连续患者接受了治疗。其中，320/551（58%）仅接受植入治疗（第一组），231/551（42%）——被视为高风险患者——还接受了中等剂量（45 Gy）的外照射治疗（第二组）。第一组的中位随访时间为55个月，第二组为60个月。7年时，第一组患者生化无进展（前列腺特异性抗原（PSA）≤1.0 ng/mL）的精算生存率为80%，8年时，第二组患者为65%。如果患者未接受过经尿道前列腺切除术，则并发症极少。结果表明，组织间放射治疗是临床局限性前列腺癌的一种有效治疗方法。
